Recent Outcomes of Surgical Redo Aortic Valve Replacement in Prosthetic Valve Failure
The Thoracic and Cardiovascular Surgeon · 01.06.2025 · 73 (04) · 279-287
DOI: 10.1055/a-2281-1897 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.06.2025. Verfasst von Yoonjin Kang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic…. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve, Heart Valve Prosthesis Implantation, Prosthesis Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
As redo surgical aortic valve replacement (AVR) is relatively high risk, valve-in-valve transcatheter AVR has emerged as an alternative for failed prostheses. However, the majority of studies are outdated. This study assessed the current clinical outcomes of redo AVR. Methods and Results This study enrolled 324 patients who underwent redo AVR due to prosthetic valve failure from 2010 to 2021 in four tertiary centers. The primary outcome was operative mortality. The secondary outcomes were overall survival, cardiac death, and aortic valve-related events. Logistic regression analysis, clustered Cox proportional hazards models, and competing risk analysis were used to evaluate the independent risk factors. Redo AVR was performed in 242 patients without endocarditis and 82 patients with endocarditis. Overall operative mortality was 4.6% (15 deaths). Excluding patients with endocarditis, the operative mortality of redo AVR decreased to 2.5%. Multivariate analyses demonstrated that endocarditis (hazard ratio [HR]: 3.990, p = 0.014), longer cardiopulmonary bypass time (HR: 1.006, p = 0.037), and lower left ventricular ejection fraction (LVEF) (HR: 0.956, p = 0.034) were risk factors of operative mortality. Endocarditis and lower LVEF were independent predictors of overall survival.
Conclusion
The relatively high risk of redo AVR was due to reoperation for prosthetic valve endocarditis. The outcomes of redo AVR for nonendocarditis are excellent. Our findings suggest that patients without endocarditis, especially with acceptable LVEF, can be treated safely with redo AVR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea.
- Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Republic of Korea.
- Department of Thoracic and Cardiovascular Surgery, Heart Stroke Vascular Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Kyung Hwan Kim
Zitieren
APA
Kang, Y., Soehartono, N. A., Choi, J. W., Kim, K. H., Hwang, H. Y., Kim, J. B., Kim, H. R., Lee, S. H., & Cho, Y. H. (2025). Recent Outcomes of Surgical Redo Aortic Valve Replacement in Prosthetic Valve Failure. The Thoracic and Cardiovascular Surgeon, 73(04), 279-287. https://doi.org/10.1055/a-2281-1897
Vancouver
Kang Y, Soehartono NA, Choi JW, Kim KH, Hwang HY, Kim JB, et al. Recent Outcomes of Surgical Redo Aortic Valve Replacement in Prosthetic Valve Failure. The Thoracic and Cardiovascular Surgeon. 2025;73(04):279-287. doi:10.1055/a-2281-1897
BibTeX
@article{Kang2025,
author = {Kang, Yoonjin and Soehartono, Nazla Amanda and Choi, Jae Woong and Kim, Kyung Hwan and Hwang, Ho Young and Kim, Joon Bum and Kim, Hong Rae and Lee, Seung Hyun and Cho, Yang Hyun},
title = {Recent Outcomes of Surgical Redo Aortic Valve Replacement in Prosthetic Valve Failure},
journal = {The Thoracic and Cardiovascular Surgeon},
year = {2025},
volume = {73},
number = {04},
pages = {279--287},
doi = {10.1055/a-2281-1897}
}
EUVIMED